Comment on basal cell carcinoma rebound after cessation of vismodegib in an individual with basal cell nevus syndrome

Dermatologic Surgery

Volumn 39, Issue 9, 2013, Pages 1413-1414

  Ally, Mina S ^a   Wysong, Ashley ^a   Tang, Jean Y ^a   Aasi, Sumaira ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VISMODEGIB;

BASAL CELL CARCINOMA; BASAL CELL NEVUS SYNDROME; CANCER RECURRENCE; CASE REPORT; DRUG EFFECT; DRUG WITHDRAWAL; FIBROSIS; HIGH RISK PATIENT; HUMAN; LETTER; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT;

ANILIDES; ANTINEOPLASTIC AGENTS; BASAL CELL NEVUS SYNDROME; FEMALE; HUMANS; PYRIDINES; SKIN NEOPLASMS;

EID: 84883555912     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/dsu.12250     Document Type: Letter

References (4)

1. Wolfe CM, Green WH, Cognetta AB Jr, Hatfield HK,. Basal cell carcinoma rebound after cessation of vismodegib in a nevoid basal cell carcinoma syndrome patient. Dermatol Surg 2012; 38: 1863-6.
2. Tang JY, Mackay-Wiggan JM, Aszterbaum M, Yauch RL, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med 2012; 366: 2180-8.
3. Sekulic A, Migden MR, Oro AE, Dirix L, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012; 366: 2171-9.
4. Hassanein AM, Proper SA, Depcik-Smith ND, Flowers FP,. Peritumoral fibrosis in basal cell and squamous cell carcinoma mimicking perineural invasion: potential pitfall in Mohs micrographic surgery. Dermatol Surg 2005; 31: 1101-6.